Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol
Authors
Keywords
Rheumatoid Arthritis, Infliximab, Etanercept, Adalimumab, Certolizumab Pegol
Journal
BIODRUGS
Volume 28, Issue S1, Pages 15-23
Publisher
Springer Nature
Online
2014-03-31
DOI
10.1007/s40259-013-0064-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SAT0479 Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: A systematic review of the literature with a meta-analysis
- (2014) S. Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- The Immunogenicity of Polyethylene Glycol: Facts and Fiction
- (2013) Huub Schellekens et al. PHARMACEUTICAL RESEARCH
- Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab
- (2012) Chamaida Plasencia et al. ANNALS OF THE RHEUMATIC DISEASES
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles
- (2012) Hiroyuki Koide et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials
- (2012) VIBEKE STRAND et al. JOURNAL OF RHEUMATOLOGY
- Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C
- (2012) F. Matsuda et al. JOURNAL OF VIRAL HEPATITIS
- Impact of Large Aggregated Uricases and PEG Diol on Accelerated Blood Clearance of PEGylated Canine Uricase
- (2012) Chun Zhang et al. PLoS One
- State of the art in PEGylation: The great versatility achieved after forty years of research
- (2011) Gianfranco Pasut et al. JOURNAL OF CONTROLLED RELEASE
- Certolizumab Pegol
- (2010) Niti Goel et al. mAbs
- Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
- (2009) Roland E. Kontermann BIODRUGS
- A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis
- (2009) B D Lacroix et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis
- (2009) Roger Palframan et al. JOURNAL OF IMMUNOLOGICAL METHODS
- A New PEG−β-Alanine Active Derivative for Releasable Protein Conjugation
- (2008) Gianfranco Pasut et al. BIOCONJUGATE CHEMISTRY
- A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease
- (2008) Tim Bourne et al. BIODRUGS
- The Impact of PEGylation on Biological Therapies
- (2008) Francesco M Veronese et al. BIODRUGS
- The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
- (2008) C.Simone Fishburn JOURNAL OF PHARMACEUTICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search